Study register · detailRCT · Irritable Bowel Syndrome · 2011
Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome.
Wong et al.·GastroenterologyImpact 0.5
Clear benefitGRADEModerate99 citations
Samplen = 75 Pat.
Durationunclear
ControlPlacebo, single dose
EndpointColonic motility index
Blindingdoppelblind
DesignRCT
Cannabinoidthc
Max. dose5.0 mg
Routeoral
”Key finding
Dronabinol reduced fasting proximal and distal left colonic motility compared with placebo, especially in diarrhea-predominant or alternating IBS; colonic compliance was increased.
Summary
Pharmacogenetic RCT, n=75 IBS patients (35 IBS-C, 35 IBS-D, 5 IBS-A), dronabinol (2,5 mg/5 mg) vs. placebo. Dronabinol reduced fasting proximal colonic motility index (MI) overall p=0,05 (5 mg: p=0,046) and increased colonic compliance (p=0,058). Largest effects in IBS-D/IBS-A: proximal MI p=0,022, compliance p=0,03. CNR1 rs806378 (CC vs. CT/TT) influenced fasting proximal MI (p=0,075).
InterventionDronabinol (non-selective cannabinoid receptor agonist), single dose 2,5 mg or 5,0 mg orally
C
ControlPlacebo, single dose
O
OutcomeDronabinol 5 mg reduced the fasting proximal left colonic motility index (MI) vs. placebo (p=0,046); strongest effects in IBS-D/IBS-M (proximal MI p=0,022; compliance p=0,03)
Confidence in the evidence
Very lowLowModerateHigh
Moderate
The third of four GRADE levels, the effect estimate is probably reliable.
Downgraded for
Imprecision
Quality profile
Sample size★★★★★
BlindingDouble-blind
Effect sizeClear benefit
Citations / year★★★★★
Authors
Wong BS, Camilleri M, Busciglio I, Carlson P, Szarka LA, Burton D, Zinsmeister AR
Background & Aims: Cannabinoid receptors are located on cholinergic neurons. Genetic variants that affect endocannabinoid metabolism are associated with colonic transit in patients with irritable bowel syndrome (IBS) with diarrhea. We compared the effects of dronabinol, a nonselective agonist of the cannabinoid receptor, with those of placebo on colonic motility and sensation in patients with IBS, and examined the effects of IBS subtype and specific genetic variants in cannabinoid mechanisms.
Methods: Seventy-five individuals with IBS (35 with IBS with constipation, 35 with IBS with diarrhea, and with 5 IBS alternating) were randomly assigned to groups that were given 1 dose of placebo or 2.5 mg or 5.0 mg dronabinol. We assessed left colonic compliance, motility index (MI), tone, and sensation during fasting and after a meal. We analyzed the single nucleotide polymorphisms CNR1 rs806378, fatty acid amide hydrolase (FAAH) rs324420, and MGLL rs4881.
Results: In all patients, dronabinol decreased fasting proximal left colonic MI compared with placebo (overall P = .05; for 5 mg dronabinol, P = .046), decreased fasting distal left colonic MI (overall P = .08; for 5 mg, P = .13), and increased colonic compliance (P = .058). The effects of dronabinol were greatest in patients with IBS with diarrhea or IBS alternating (proximal colonic MI, overall P = .022; compliance, overall P = .03). Dronabinol did not alter sensation or tone. CNR1 rs806378 (CC vs CT/TT) appeared to affect fasting proximal MI in all patients with IBS (P = .075). Dronabinol affected fasting distal MI in patients, regardless of FAAH rs324420 variant (CA/AA vs CC) (P = .046); the greatest effects were observed among IBS with constipation patients with the FAAH CC variant (P = .045). Dronabinol affected fasting proximal MI in patients with IBS with diarrhea or alternating with the variant FAAH CA/AA (P = .013).
Conclusions: In patients with IBS with diarrhea or alternating, dronabinol reduces fasting colonic motility; FAAH and CNR1 variants could influence the effects of this drug on colonic motility.